Neuro-ophthalmic challenges and multi-morbidity in vasculitis among the older adults.

INTRODUCTION Vasculitides are a heterogeneous group of disorders producing inflammation of blood vessels (e.g. arteries or veins). All major vasculitides potentially have ophthalmological symptoms and signs including visual loss. Co-morbidity, multimorbidity, polypharmacy and geriatric syndromes all play important roles in patient outcomes for these rheumatic conditions in the elderly. This monograph reviews the NCBI PubMed database (Feb 2023) literature on the neuro-ophthalmic and geriatric considerations in vasculitis. AREAS COVERED Cogan Syndrome, Granulomatosis with Polyangiitis, Giant Cell Arteritis, Polyarteritis Nodosa, Takayasu Arteritis, Vasculitis epidemiology, neuro-ophthalmological symptoms. EXPERT OPINION Geriatric patient care for vasculitis with neuro-ophthalmological manifestations can be complicated by the interplay of multiple co-morbidities, polypharmacy, and specific geriatric syndromes. The valuation and treatment of vasculitis and the complications associated with the disease can negatively impact patient care. Advances in noninvasive imaging and updates in diagnostic criteria have enabled increased identification of patients at earlier stages with less severe disease burden. Novel therapeutic agents can be glucocorticoid sparing and might reduce the adverse effects of chronic steroid use. Holistic care models like the 5 M geriatric care model (mind, mobility, medications, multicomplexity, and matters most) allow patients' needs to be in the forefront with biopsychosocial aspects of a patient being addressed.

[1]  P. Heeringa,et al.  Metabolic features and glucocorticoid-induced comorbidities in patients with giant cell arteritis and polymyalgia rheumatica in a Dutch and Danish cohort , 2023, RMD Open.

[2]  P. Merkel,et al.  2022 American College of Rheumatology/EULAR Classification Criteria for Giant Cell Arteritis , 2022, Arthritis & rheumatology.

[3]  E. Vicente-Rabaneda,et al.  Utility of tocilizumab in autoimmune eye diseases , 2022, Expert opinion on biological therapy.

[4]  A. Boonen,et al.  Challenges in the management of older patients with inflammatory rheumatic diseases , 2022, Nature Reviews Rheumatology.

[5]  E. Vicente-Rabaneda,et al.  Advances in the Treatment of Giant Cell Arteritis , 2022, Journal of clinical medicine.

[6]  J. Springer,et al.  Diagnostic and Therapeutic Challenges of Vasculitis. , 2022, The Canadian journal of cardiology.

[7]  M. Harigai,et al.  Avacopan, a Selective C5a Receptor Antagonist, for Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis. , 2022, Modern rheumatology.

[8]  J. Burns,et al.  Global epidemiology of vasculitis , 2021, Nature Reviews Rheumatology.

[9]  Marina F Englesakis,et al.  Effects of comprehensive geriatric care models on postoperative outcomes in geriatric surgical patients: a systematic review and meta-analysis , 2021, BMC Anesthesiology.

[10]  R. Mustafa,et al.  Giant Cell Arteritis: A Systematic Review and Meta‐Analysis of Test Accuracy and Benefits and Harms of Common Treatments , 2021, ACR open rheumatology.

[11]  C. Crowson,et al.  Prevalence of Takayasu Arteritis: A Population-based Study , 2021, The Journal of Rheumatology.

[12]  P. Cacoub,et al.  Medium- and Large-Vessel Vasculitis. , 2021, Circulation.

[13]  J. Pope,et al.  A meta-analysis of the epidemiology of giant cell arteritis across time and space , 2020, Arthritis Research & Therapy.

[14]  R. Luqmani,et al.  Treatment of Giant Cell Arteritis and Takayasu Arteritis—Current and Future , 2020, Current Rheumatology Reports.

[15]  H. Patel,et al.  Multi-Morbidity and Polypharmacy in Older People: Challenges and Opportunities for Clinical Practice , 2020, Geriatrics.

[16]  P. Merkel,et al.  ANCA-associated vasculitis , 2020, Nature Reviews Disease Primers.

[17]  E. Matteson,et al.  Monitoring and long-term management of giant cell arteritis and polymyalgia rheumatica , 2020, Nature Reviews Rheumatology.

[18]  K. Temprano,et al.  Cogan’s Syndrome: Clinical Presentations and Update on Treatment , 2020, Current Allergy and Asthma Reports.

[19]  S. Palioura,et al.  Bilateral interstitial keratitis, erythema nodosum and atrial fibrillation as presenting signs of polyarteritis nodosa , 2020, American journal of ophthalmology case reports.

[20]  M. Ko,et al.  Neuro-Ophthalmologic Complications of Giant Cell Arteritis: Diagnosis and Treatment , 2019, Seminars in Neurology.

[21]  C. Turesson,et al.  2018 Update of the EULAR recommendations for the management of large vessel vasculitis , 2019, Annals of the rheumatic diseases.

[22]  L. Arnaud,et al.  Large-vessel vasculitis diagnosed between 50 and 60 years: Case-control study based on 183 cases and 183 controls aged over 60 years. , 2019, Autoimmunity reviews.

[23]  L. Mouthon,et al.  Ocular involvement in granulomatosis with polyangiitis: A single-center cohort study on 63 patients. , 2019, Autoimmunity reviews.

[24]  L. Guillevin,et al.  Polyarteritis Nodosa Neurologic Manifestations. , 2019, Neurologic clinics.

[25]  I. Chatziralli,et al.  Ocular Manifestations of Granulomatosis with Polyangiitis: A Review of the Literature , 2019, Ophthalmology and Therapy.

[26]  E. Tombetti,et al.  Takayasu arteritis: advanced understanding is leading to new horizons , 2019, Rheumatology.

[27]  Y. Wang,et al.  Ocular and orbital exacerbation after rituximab therapy for granulomatosis with polyangiitis. , 2019, Canadian journal of ophthalmology. Journal canadien d'ophtalmologie.

[28]  Z. Amoura,et al.  Giant-cell arteritis-related mortality in France: A multiple-cause-of-death analysis. , 2018, Autoimmunity reviews.

[29]  R. Caporali,et al.  Aging in Primary Systemic Vasculitis: Implications for Diagnosis, Clinical Manifestations, and Management , 2018, Drugs & Aging.

[30]  W. Frishman,et al.  Tocilizumab in Giant Cell Arteritis , 2018, Cardiology in review.

[31]  R. Caporali,et al.  20 years of experience with tumour necrosis factor inhibitors: what have we learned? , 2018, Rheumatology.

[32]  G. Kuchel Frailty and Resilience as Outcome Measures in Clinical Trials and Geriatric Care: Are We Getting Any Closer? , 2018, Journal of the American Geriatrics Society.

[33]  P. Merkel,et al.  Evaluation of damage in giant cell arteritis , 2018, Rheumatology.

[34]  J. Rizzo,et al.  Ophthalmic manifestations of giant cell arteritis. , 2018, Rheumatology.

[35]  M. Isobe,et al.  Efficacy and safety of tocilizumab in patients with refractory Takayasu arteritis: results from a randomised, double-blind, placebo-controlled, phase 3 trial in Japan (the TAKT study) , 2017, Annals of the rheumatic diseases.

[36]  Gillian E. Caughey,et al.  What is polypharmacy? A systematic review of definitions , 2017, BMC Geriatrics.

[37]  H. Wald,et al.  Comprehensive geriatric assessment for older adults admitted to hospital. , 2017, The Cochrane database of systematic reviews.

[38]  E. Matteson,et al.  The Epidemiology of Antineutrophil Cytoplasmic Autoantibody–Associated Vasculitis in Olmsted County, Minnesota , 2017, Arthritis & rheumatology.

[39]  B. Bonnotte,et al.  Recent advances in our understanding of giant cell arteritis pathogenesis. , 2017, Autoimmunity reviews.

[40]  K. Aksu,et al.  What is new in management of Takayasu arteritis? , 2017, Presse medicale.

[41]  H. Ahn,et al.  Incidence, prevalence, mortality and causes of death in Takayasu Arteritis in Korea - A nationwide, population-based study. , 2017, International journal of cardiology.

[42]  E. Matteson,et al.  Evaluating the Incidence of Arteritic Ischemic Optic Neuropathy and Other Causes of Vision Loss from Giant Cell Arteritis. , 2016, Ophthalmology.

[43]  C. Pui,et al.  Preventing and Managing Toxicities of High-Dose Methotrexate , 2016, The oncologist.

[44]  E. Matteson,et al.  The spectrum of giant cell arteritis and polymyalgia rheumatica: revisiting the concept of the disease , 2016, Rheumatology.

[45]  J. Llorca,et al.  Giant Cell Arteritis: Visual Loss Is Our Major Concern , 2016, The Journal of Rheumatology.

[46]  B. Roche,et al.  Incidence of Severe Infections and Infection‐Related Mortality During the Course of Giant Cell Arteritis: A Multicenter, Prospective, Double‐Cohort Study , 2016, Arthritis & rheumatology.

[47]  M. Oray,et al.  Long-term side effects of glucocorticoids , 2016, Expert opinion on drug safety.

[48]  C. Salvarani,et al.  Epidemiology of granulomatosis with polyangiitis (Wegener's granulomatosis) in Northern Italy: a 15-year population-based study. , 2014, Seminars in arthritis and rheumatism.

[49]  A. Kessel,et al.  Cogan syndrome--pathogenesis, clinical variants and treatment approaches. , 2014, Autoimmunity reviews.

[50]  P. Merkel,et al.  Distribution of arterial lesions in Takayasu's arteritis and giant cell arteritis , 2012, Annals of the rheumatic diseases.

[51]  Y. J. Liao,et al.  Giant cell arteritis: immune and vascular aging as disease risk factors , 2011, Arthritis research & therapy.

[52]  T. Therneau,et al.  The lifetime risk of adult-onset rheumatoid arthritis and other inflammatory autoimmune rheumatic diseases. , 2011, Arthritis and rheumatism.

[53]  C. Kallenberg Pathophysiology of ANCA-Associated Small Vessel Vasculitis , 2010, Current rheumatology reports.

[54]  D A Bloch,et al.  The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. , 2010, Arthritis and rheumatism.

[55]  K. Barraclough,et al.  BSR and BHPR guidelines for the management of giant cell arteritis. , 2010, Rheumatology.

[56]  D. Scott,et al.  Epidemiology of ANCA-associated vasculitis. , 2010, Rheumatic diseases clinics of North America.

[57]  L. Mouthon,et al.  Clinical features and outcomes in 348 patients with polyarteritis nodosa: a systematic retrospective study of patients diagnosed between 1963 and 2005 and entered into the French Vasculitis Study Group Database. , 2010, Arthritis and rheumatism.

[58]  L. Jacobsson,et al.  Incidence and survival rates in Wegener's granulomatosis, microscopic polyangiitis, Churg-Strauss syndrome and polyarteritis nodosa. , 2009, Rheumatology.

[59]  S. Gabriel,et al.  Increase in age at onset of giant cell arteritis: a population-based study , 2009, Annals of the rheumatic diseases.

[60]  D. Scott,et al.  The epidemiology of Takayasu arteritis in the UK. , 2009, Rheumatology.

[61]  E. Matteson,et al.  Cogan syndrome: a retrospective review of 60 patients throughout a half century. , 2006, Mayo Clinic proceedings.

[62]  L. Mortelmans,et al.  Repetitive 18F-fluorodeoxyglucose positron emission tomography in giant cell arteritis: a prospective study of 35 patients. , 2006, Arthritis and rheumatism.

[63]  J. Llorca,et al.  Giant Cell Arteritis: Disease Patterns of Clinical Presentation in a Series of 240 Patients , 2005 .

[64]  C. Feighery,et al.  Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. , 2005, Arthritis and rheumatism.

[65]  P. Savino,et al.  Poor prognosis of visual outcome after visual loss from giant cell arteritis. , 2005, Ophthalmology.

[66]  S. Aymé,et al.  Prevalences of polyarteritis nodosa, microscopic polyangiitis, Wegener's granulomatosis, and Churg-Strauss syndrome in a French urban multiethnic population in 2000: a capture-recapture estimate. , 2004, Arthritis and rheumatism.

[67]  L. Cimino,et al.  Cogan Syndrome , 2002, Cornea.

[68]  N. Miller,et al.  CHOROIDAL INFARCTION, ANTERIOR ISCHEMIC OPTIC NEUROPATHY, AND CENTRAL RETINAL ARTERY OCCLUSION FROM POLYARTERITIS NODOSA , 2001, Retina.

[69]  L. Fried,et al.  Frailty in older adults: evidence for a phenotype. , 2001, The journals of gerontology. Series A, Biological sciences and medical sciences.

[70]  J. Jover,et al.  Combined Treatment of Giant-Cell Arteritis with Methotrexate and Prednisone , 2001, Annals of Internal Medicine.

[71]  D. Scott,et al.  Epidemiology of systemic vasculitis: a ten-year study in the United Kingdom. , 2000, Arthritis and rheumatism.

[72]  F. Numano,et al.  Angiographic findings of Takayasu arteritis: new classification. , 1996, International journal of cardiology.

[73]  J. Provenzale,et al.  Neuroradiologic findings in polyarteritis nodosa. , 1996, AJNR. American journal of neuroradiology.

[74]  M. Cid,et al.  Clinical usefulness of temporal artery biopsy. , 1987, Annals of the rheumatic diseases.

[75]  H. Yazıcı,et al.  Influence of age of onset and patient's sex on the prevalence and severity of manifestations of Behçet's syndrome. , 1984, Annals of the rheumatic diseases.

[76]  B. Haynes,et al.  Cogan syndrome: studies in thirteen patients, long-term follow-up, and a review of the literature. , 1980, Medicine.

[77]  M. Grainge,et al.  Systematic review and meta analysis A systematic review and meta-analysis of the incidence rate of Takayasu arteritis , 2021 .

[78]  N. Arden,et al.  The relative risk of aortic aneurysm in patients with giant cell arteritis compared with the general population of the UK. , 2015, Annals of the rheumatic diseases.

[79]  M. LaValley,et al.  Gender-specific differences in Adamantiades-Behçet's disease manifestations: an analysis of the German registry and meta-analysis of data from the literature. , 2015, Rheumatology.

[80]  M. Cesari,et al.  The frailty phenotype and the frailty index: different instruments for different purposes. , 2014, Age and ageing.

[81]  P. Merkel,et al.  2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. , 2013, Arthritis and rheumatism.

[82]  J. Barrier Treatment of giant cell arteritis. , 1994, Annales de medecine interne.